Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.26
- Piotroski Score 7.00
- Grade Buy
- Symbol (GSK)
- Company GSK plc
- Price $43.01
- Changes Percentage (-0.24%)
- Change -$0.11
- Day Low $42.95
- Day High $43.44
- Year High $45.93
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
- Last Earnings 07/31/2024
- Ex-Dividend for 5/16 Dividend 08/16/2024
- Dividend Payable 10/10/2024
- Today N/A
- Next Earnings (Estimated) 10/30/2024
- Fiscal Year End N/A
- Average Stock Price Target $53.00
- High Stock Price Target $85.00
- Low Stock Price Target $36.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $2.78
- Trailing P/E Ratio 14.82
- Forward P/E Ratio 14.82
- P/E Growth 14.82
- Net Income $4.93 B
Income Statement
Quarterly
Annual
Latest News of GSK
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Stocks Generating Improved Relative Strength: GSK ADR
GSK ADR's RS Rating increased from 63 to 72, indicating a positive trend. Stocks with RS Ratings over 80 in the early stages often perform well. GSK ADR is forming a cup without handle pattern with a ...
By Investor's Business Daily | 1 week ago -
With 86% institutional ownership, GSK plc (LON:GSK) is a favorite amongst the big guns
Institutional investors hold a significant stake in GSK, making the stock price vulnerable to their decisions. With over 86% ownership, institutions play a crucial role in influencing the company's pe...
By Yahoo! Finance | 1 week ago -
GSK shares rise on Delaware Supreme Court appeal in Zantac case
Shares of GSK plc (LON:GSK) rose as the Delaware Supreme Court granted an interlocutory review of a previous court decision in a case alleging a link between ranitidine in Zantac and cancer....
By Yahoo! Finance | 2 weeks ago
